- Home
- BLKB vs TVTX Comparison
BLKB vs TVTX Comparison
Compare BLKB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | TVTX |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLKB | TVTX |
|---|---|---|
| Price | $62.00 | $34.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $70.50 | $37.21 |
| AVG Volume (30 Days) | 353.7K | ★ 1.4M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,136,093,000.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.36 |
| Revenue Next Year | $4.09 | $37.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $54.56 | $12.91 |
| 52 Week High | $81.63 | $37.50 |
Technical Indicators
Market Signals| Indicator | BLKB | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 52.61 |
| Support Level | $60.62 | $33.84 |
| Resistance Level | $63.59 | $35.97 |
| Average True Range (ATR) | 1.89 | 1.45 |
| MACD | 0.55 | -0.34 |
| Stochastic Oscillator | 70.50 | 25.06 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.